Hyperion Defi (HYPD) Net Equity Issued and Repurchased (2017 - 2026)
Hyperion Defi (HYPD) posted quarterly Net Equity Issued and Repurchased of $6.7 million for Q1 2026, up 17.54% year-over-year from $5.7 million in Q1 2025, and up 17.54% quarter-over-quarter from $5.7 million in Q1 2025.
Hyperion Defi (HYPD) Net Equity Issued and Repurchased (2017 - 2026) Analysis & Trends
Hyperion Defi (HYPD) has reported Net Equity Issued and Repurchased for 7 consecutive years, with $6.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Equity Issued and Repurchased rose 17.54% year-over-year to $6.7 million; the TTM figure through Mar 2026 stood at $15.6 million (up 75.28% YoY), while the FY2025 annual figure was $39.4 million, up 556.67% from the prior year.
- Net Equity Issued and Repurchased climbed to $6.7 million in Q1 2026 per HYPD's latest filing, from $5.7 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $6.7 million in Q1 2026 and bottomed at $100449.0 in Q3 2023.
- Historically, Net Equity Issued and Repurchased has averaged $3.4 million across 5 years, with a median of $3.6 million in 2022.
- Annual changes were most pronounced in 2023 — Net Equity Issued and Repurchased plunged 96.76% — and 2024, when it surged 3882.12%.
- Hyperion Defi's Net Equity Issued and Repurchased stood at $3.1 million in 2022, then slumped by 96.76% to $100449.0 in 2023, then soared by 3882.12% to $4.0 million in 2024, then soared by 42.5% to $5.7 million in 2025, then rose by 17.54% to $6.7 million in 2026.
- Business Quant data shows HYPD's Net Equity Issued and Repurchased at $6.7 million in Q1 2026, $5.7 million in Q1 2025, and $4.0 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Hyperion Defi | 44.93 Mn | 35.29 Mn | 357,693.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.70 Mn |
| Mar 31, 2026 | 6.70 Mn |
| Mar 31, 2025 | 5.70 Mn |
| Mar 31, 2025 | 5.70 Mn |
| Sep 30, 2024 | 4.00 Mn |
| Sep 30, 2024 | 4.00 Mn |
| Sep 30, 2023 | 100,449.00 |
| Sep 30, 2023 | 100,449.00 |
| Sep 30, 2022 | 3.10 Mn |
| Sep 30, 2022 | 3.10 Mn |
| Mar 31, 2022 | 900,000.00 |
| Mar 31, 2022 | 900,000.00 |
| Sep 30, 2018 | -25.09 Mn |
| Sep 30, 2018 | -25.09 Mn |
| Mar 31, 2018 | 25.09 Mn |
| Mar 31, 2018 | 25.09 Mn |
| Sep 30, 2017 | 6.41 Mn |
| Sep 30, 2017 | 6.41 Mn |